These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7541528)

  • 1. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer.
    Carter HB; Pearson JD; Metter EJ; Chan DW; Andres R; Fozard JL; Rosner W; Walsh PC
    Prostate; 1995 Jul; 27(1):25-31. PubMed ID: 7541528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.
    Carter HB; Pearson JD; Metter EJ; Brant LJ; Chan DW; Andres R; Fozard JL; Walsh PC
    JAMA; 1992 Apr 22-29; 267(16):2215-20. PubMed ID: 1372942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced circulating androgen bioactivity in patients with prostate cancer.
    Raivio T; Santti H; Schatzl G; Gsur A; Haidinger G; Palvimo JJ; Jänne OA; Madersbacher S
    Prostate; 2003 May; 55(3):194-8. PubMed ID: 12692785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of androgen deficiency and replacement on prostate zonal volumes.
    Jin B; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):437-45. PubMed ID: 11318778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baldness, benign prostate hyperplasia, prostate cancer and androgen levels.
    Faydaci G; Bilal E; Necmettin P; Fatih T; Asuman O; Uğur K
    Aging Male; 2008 Dec; 11(4):189-92. PubMed ID: 19172550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
    Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
    Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada.
    Wu AH; Whittemore AS; Kolonel LN; John EM; Gallagher RP; West DW; Hankin J; Teh CZ; Dreon DM; Paffenbarger RS
    Cancer Epidemiol Biomarkers Prev; 1995; 4(7):735-41. PubMed ID: 8672990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of radical prostatectomy on serum hormone levels.
    Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
    J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of sex hormone levels and risk of prostate cancer.
    Gann PH; Hennekens CH; Ma J; Longcope C; Stampfer MJ
    J Natl Cancer Inst; 1996 Aug; 88(16):1118-26. PubMed ID: 8757191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum concentrations of sex hormones in men with severe lower urinary tract symptoms and benign prostatic hyperplasia.
    Tan MO; Karabiyik I; Uygur MC; Diker Y; Erol D
    Int Urol Nephrol; 2003; 35(3):357-63. PubMed ID: 15160539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease.
    Carter HB; Morrell CH; Pearson JD; Brant LJ; Plato CC; Metter EJ; Chan DW; Fozard JL; Walsh PC
    Cancer Res; 1992 Jun; 52(12):3323-8. PubMed ID: 1375867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia.
    Partin AW; Oesterling JE; Epstein JI; Horton R; Walsh PC
    J Urol; 1991 Feb; 145(2):405-9. PubMed ID: 1703242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer.
    Gonzalez-Barcena D; Vadillo-Buenfil M; Gomez-Orta F; Fuentes Garcia M; Cardenas-Cornejo I; Graef-Sanchez A; Comaru-Schally AM; Schally AV
    Prostate; 1994; 24(2):84-92. PubMed ID: 7508623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer.
    Rannikko S; Adlercreutz H
    Prostate; 1983; 4(3):223-9. PubMed ID: 6189106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone concentration, metabolic disorders and immunoexpression of androgen and estrogen-alpha receptors in men with benign prostatic hyperplasia and testosterone deficiency syndrome.
    Ryl A; Rotter I; Slojewski M; Dolegowska B; Grabowska M; Baranowska-Bosiacka I; Laszczynska M
    Folia Histochem Cytobiol; 2015; 53(3):227-35. PubMed ID: 26400665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do differences in age specific androgenic steroid hormone levels account for differing prostate cancer rates between Arabs and Caucasians?
    Kehinde EO; Akanji AO; Al-Hunayan A; Memon A; Luqmani Y; Al-Awadi KA; Varghese R; Bashir AA; Daar AS
    Int J Urol; 2006 Apr; 13(4):354-61. PubMed ID: 16734850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer.
    Pearson JD; Luderer AA; Metter EJ; Partin AW; Chan DW; Fozard JL; Carter HB
    Urology; 1996 Dec; 48(6A Suppl):4-9. PubMed ID: 8973693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer risk: the significance of differences in age related changes in serum conjugated and unconjugated steroid hormone concentrations between Arab and Caucasian men.
    Kehinde EO; Akanji AO; Memon A; Bashir AA; Daar AS; Al-Awadi KA; Fatinikun T
    Int Urol Nephrol; 2006; 38(1):33-44. PubMed ID: 16502050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
    Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
    Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.